Inhibition of intestinal microflora β-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats

被引:99
作者
Takasuna, K
Hagiwara, T
Hirohashi, M
Kato, M
Nomura, M
Nagai, E
Yokoi, T
Kamataki, T
机构
[1] Daiichi Pharmaceut Co Ltd, Drug Safety Res Lab, Edogawa Ku, Tokyo 134, Japan
[2] Daiichi Pharmaceut Co Ltd, Med Prod Management & market Planning, Edogawa Ku, Tokyo 134, Japan
[3] Hokkaido Univ, Fac Pharmaceut Sci, Div Drug Metab, Kita Ku, Sapporo, Hokkaido 060, Japan
关键词
CPT-11; SN-38; glucuronide; diarrhea; beta-glucuronidase;
D O I
10.1007/s002800050818
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: SN-38, a metabolite of irinotecan hydrochloride (CPT-11), is considered to play a key role in the development of diarrhea as well as in the antitumor activity of CPT-11. We have previously found that the inhibition of beta-glucuronidase, which hydrolyzes detoxified SN-38 (SN-38 glucuronide) to reform SN-38, in the lumen by eliminating the intestinal microflora with antibiotics, markedly ameliorates the intestinal toxicity of CPT-11 in rats. In this study we compared the disposition of CPT-11 and its metabolites in rats treated with and without antibiotics. Methods: Rats were given drinking water containing 1 mg/ml penicillin and 2 mg/ml streptomycin from 5 days before the administration of CPT-11 (60 mg/kg i.v.) and throughout the experiment. CPT-11, SN-38 glucuronide and SN-38 concentrations in the blood, intestinal tissues and intestinal luminal contents were determined by HPLC. Results: Antibiotics had little or no effect on the pharmacokinetics of CPT-11, SN-38 glucuronide or SN-38 in the blood, or in the tissues or contents of the small intestine, which has less beta-glucuronidase activity in its luminal contents. In contrast, antibiotics markedly reduced the AUC(1-24) (h) of SN-38 (by about 85%) in the large intestine tissue without changing that of CPT-11, and this was accompanied by a complete inhibition of the deconjugation of SN-38 glucuronide in the luminal contents. Conclusion: These results suggest that SN-38, which results from the hydrolysis of SN-38 glucuronide by beta-glucuronidase in the intestinal microflora, contributes considerably to the distribution of SN-38 in the large intestine tissue, and that inhibition of the beta-glucuronidase activity by antibiotics results in decreased accumulation of SN-38 in the large intestine.
引用
收藏
页码:280 / 286
页数:7
相关论文
共 26 条
  • [1] PHASE-I AND PHARMACOLOGICAL STUDIES OF THE CAMPTOTHECIN ANALOG IRINOTECAN ADMINISTERED EVERY 3 WEEKS IN CANCER-PATIENTS
    ABIGERGES, D
    CHABOT, GG
    ARMAND, JP
    HERAIT, P
    GOUYETTE, A
    GANDIA, D
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (01) : 210 - 221
  • [2] IRINOTECAN (CPT-11) HIGH-DOSE ESCALATION USING INTENSIVE HIGH-DOSE LOPERAMIDE TO CONTROL DIARRHEA
    ABIGERGES, D
    ARMAND, JP
    CHABOT, GG
    DACOSTA, L
    FADEL, E
    COTE, C
    HERAIT, P
    GANDIA, D
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (06) : 446 - 449
  • [3] RELATIONSHIP BETWEEN DEVELOPMENT OF DIARRHEA AND THE CONCENTRATION OF SN-38, AN ACTIVE METABOLITE OF CPT-11, IN THE INTESTINE AND THE BLOOD-PLASMA OF ATHYMIC MICE FOLLOWING INTRAPERITONEAL ADMINISTRATION OF CPT-11
    ARAKI, E
    ISHIKAWA, M
    IIGO, M
    KOIDE, T
    ITABASHI, M
    HOSHI, A
    [J]. JAPANESE JOURNAL OF CANCER RESEARCH, 1993, 84 (06): : 697 - 702
  • [4] IDENTIFICATION OF THE METABOLITES OF IRINOTECAN, A NEW DERIVATIVE OF CAMPTOTHECIN, IN RAT BILE AND ITS BILIARY-EXCRETION
    ATSUMI, R
    SUZUKI, W
    HAKUSUI, H
    [J]. XENOBIOTICA, 1991, 21 (09) : 1159 - 1169
  • [5] Irinotecan is an active agent in untreated patients with metastatic colorectal cancer
    Conti, JA
    Kemeny, NE
    Saltz, LB
    Huang, Y
    Tong, WP
    Chou, TC
    Sun, M
    Pulliam, S
    Gonzalez, C
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) : 709 - 715
  • [6] A PHASE-II STUDY OF CPT-11, A NEW DERIVATIVE OF CAMPTOTHECIN, FOR PREVIOUSLY UNTREATED NON-SMALL-CELL LUNG-CANCER
    FUKUOKA, M
    NIITANI, H
    SUZUKI, A
    MOTOMIYA, M
    HASEGAWA, K
    NISHIWAKI, Y
    KURIYAMA, T
    ARIYOSHI, Y
    NEGORO, S
    MASUDA, N
    NAKAJIMA, S
    TAGUCHI, T
    ASAKAWA, M
    NAKABAYASI, T
    NAKAI, T
    KURITA, Y
    KINAMERI, K
    NOMURA, K
    NAGAO, K
    SAIJO, N
    OHE, Y
    SUGIURA, T
    SHIMOKATA, K
    SAKA, H
    NEGORO, S
    NAKAJIMA, S
    TOHDA, Y
    FUJII, M
    OTA, M
    HARA, N
    HARA, Y
    FUJISAWA, K
    NAKANO, S
    ARAKI, J
    NIITANI, H
    MIYATA, Y
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (01) : 16 - 20
  • [7] GUPTA E, 1994, CANCER RES, V54, P3723
  • [8] KANEDA N, 1990, CANCER RES, V50, P1721
  • [9] KANEDA N, 1990, CANCER RES, V50, P1715
  • [10] KAWATO Y, 1991, CANCER RES, V51, P4187